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Abstract
An important elimination route of the histamine antagonist famotidine is active tubular secretion via the renal organic cation transport system. To characterize the excretion kinetics of famotidine in-vivo, the relationship between plasma concentration and urinary excretion rate was investigated in the beagle dog 
over a wide concentration range. The maximum transport capacity and the apparent Michaelis-Menten 
constant of tubular secretion were estimated.Concentration-dependent renal clearance was determined either after intravenous infusion of high doses of 
famotidine for a short time or during continuous infusion. From individual experiments only indications of saturation were observed; these could not be quantified. A tubular titration curve, in which the active tubular 
famotidine secretion was plotted against the plasma concentration, was constructed from the data from all the experiments. Active tubular secretion was calculated for each experiment separately by subtracting the 
famotidine filtration rate from the total excretion rate. A tubular transport maximum of 2400 ±  220 |ig min 1 and an apparent Michaelis-Menten constant for tubular secretion of 26 ±  4 [ig mL " 1 
(76 ±  12 |¿m) were estimated from the curve.To the best of our knowledge, this is the first time that saturation of famotidine renal clearance has been fully 
quantified in-vivo. Considering the low therapeutic plasma concentrations of famotidine (<0*1 jigmL'" ), 
these results suggest that clinically the drug has a low interactive potential.
Famotidine, a relatively new histamine H2 antagonist, is 
commonly used for the treatment of peptic ulcers. Famotidine 
is approximately eight times more potent than ranitidine and 
thirty times more potent than cimetidine at inhibiting gastric 
acid secretion. The therapeutic dosing regimen of 40 mg 
day"*1, resulting in a plasma concentration of 10- 
lOOngmL"'1, is much lower than that of either cimetidine or 
ranitidine» After intravenous administration in man, 10-28% of 
the drug is weakly bound to plasma proteins and approximately 
70% is excreted unchanged in the urine. The renal clearance of 
approximately 250mL min“ 1 clearly exceeds the glomerular 
filtration rate, and famotidine is, therefore, considered to be 
excreted by active tubular secretion (Echizen & Ishizaki 1991). 
Because famotidine is a weak base, it is secreted by the tubular 
organic cation transport system and its inhibitory potency 
against cationic drug transport has been determined in various 
in-vitro studies. Although famotidine seems to be a potent 
inhibitor of renal organic cation transport, comparable with 
cimetidine, whereas both nizatidine and ranitidine are less 
potent (Bendayan et al 1990; Boom et al 1992; Boom & Russel 
1993; Somogyi et al 1994; David et al 1995), there seems to be 
a discrepancy between data obtained in cellular and subcellular 
preparations and those obtained by studies at the organ level. 
In the isolated perfused rat kidney, cimetidine and ranitidine 
were equipotent in inhibiting triamterene clearance, whereas 
famotidine was less potent (Muirhead & Somogyi 1991). In in- 
vivo studies in rats, it was shown that cimetidine inhibited the 
tubular secretion of famotidine, but that famotidine could not 
reduce the renal clearance of cimetidine (Lin et al 1988).
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To characterize the excretion kinetics of famotidine in-vivo, 
the relationship between plasma concentration and active renal 
clearance was investigated in the beagle dog. The purpose of 
this study was to estimate the maximum transport capacity and 
the apparent Michaelis-Menten constant of tubular secretion. 
To the best of our knowledge, this is the first study in which 
these kinetic parameters have been determined for famotidine.
Materials and Methods
Materials
Famotidine was generously donated by MSD Research 
Laboratories (Rahway, USA) and famotidine powder for 
injection (Pepcidin) was obtained from MSD (Haarlem, The 
Netherlands). Braunule-T cannulas were obtained from Braun 
(Melsungen, Germany), the double-walled urinary catheter 
from Talas (Ommen, The Netherlands), and Visking 8 dialysis 
tubing from Instrumentenhandel Z. H. (The Hague, The 
Netherlands). Sodium pentobarbital was from Apharma (Arn­
hem, The Netherlands), heparin from Organon (Oss, The 
Netherlands), and atropine sulphate and mannitol were from 
OPG (Utrecht, The Netherlands). Hydrochloric acid (32%, 
analytical reagent) was from Baker (Deventer, The Nether­
lands) and 1-heptanesulphonic acid from Janssen Chimica 
(Geel, Belgium). All other chemicals were of reagent grade 
and obtained from either Sigma (St Louis, MO) or Merck 
(Darmstadt, Germany). Vac Elut manifold and Bond Elut Cjg 
columns (1 mL capacity) were from Analytichem (Habor City, 
CA).
Dogs
Male beagle dogs, 2-3 years old, were obtained from the 
Central Animals Laboratory of the University of Nijmegen.
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The dogs were housed individually with free access to tap 
water. They were fed once daily with a commercially available 
diet.
Clearance experiment
The clearance experiments were performed as described in 
detail elsewhere (Russel et al 1987). Briefly, male beagle dogs, 
13 to 16 kg, were anaesthetized by intravenous administration 
of sodium pentobarbital (30 mg kg _ l) with atropine sulphate 
(0-5%, 1 mL) as premedication. Both cephalic veins were 
cannulated (Braunule T, length 50 mm, 1-0 mm o.d. x 1-5 mm
i.d.) for blood sampling and drug administration. A constant 
infusion of 5% mannitol and 0*5% inulin (2 mLmin""1) was 
administered to obtain a sufficiently high urine flow and for 
determination of the glomerular filtration rate. During the 
experiment, body temperature and heart rate were monitored 
continuously. Famotidine (Pepcidin) was administered intra­
venously either for a short time or as a continuous infusion. 
Blood samples (7mL) were taken at regular intervals into 
heparinized tubes and plasma was separated by centrifugation 
for 6 min at 2000 g . Urine was collected quantitatively by use 
of a double-walled urinary catheter by rinsing the bladder at 
the end of each collection interval with 10 mL 0-9% NaCl 
(saline). Plasma and urine samples were stored at — 20°C until 
analysis. The dogs were left to recover for at least three weeks 
before being used again.
Analytical methods
Famotidine was analysed by high-performance liquid chro­
matography (HPLC). The Spectra Physics Analytical (Eind­
hoven, The Netherlands) system used consisted of a P2000 
binary gradient pump, an AS3000 autosampler with built-in 
column heater, a model UV1000 variable-wavelength detector 
set at 228 nm and an SP4400 integrator. Separation was per­
formed on a 125 x 4 mm i.d. stainless-steel column and a 
4 x 4  mm i.d. guard column packed with 5 jam LiChrospher 60 
RP-select B (Merck, Germany). The mobile phase was 10:90, 
v/v, acetonitrile-0’02 M, pH 3-0 phosphate buffer containing 
l*0gL” J heptanesulphonic acid. The flow rate was
1 mLmin-1 , the column temperature 40°C and the auto­
sampler temperature 4°C.
Famotidine and procaine (internal standard) were separated 
from plasma with bonded silica solid-phase extraction columns 
(Bond Elut Cis, 1 mL capacity). The plasma samples were pre­
treated by adding 1*0 mL of 0-01M sodium carbonate solution 
containing 5jxg internal standard (procaine) to 1*0 mL of 
plasma. After vortex-mixing, the sample was loaded on to 
extraction columns previously conditioned with methanol 
( 3 x 1  mL) then 0-01M sodium bicarbonate solution 
( 3 x 1  mL). The pre-treated plasma samples were passed 
through the column, which was subsequently washed with 
0-01 M sodium bicarbonate solution (5 mL). Famotidine and 
procaine were eluted from the column with 40:60, v/v, 
methanol-0-01 M, pH 5-0 citric acid (ImL) and 20 |^L was 
injected on to the column. Under these conditions the retention 
times of famotidine and internal standard were 6*5 and 13 min, 
respectively.
Urine samples were pre-treated by adding sodium carbonate 
solution (0-01M; 900 jxL) containing internal standard (pro­
caine; 5 jig) to urine (100 jaL). The urine samples were 
extracted in the same way as the plasma samples except that
the column was washed with 10 mL o f  0*01 M sodium bicar­
bonate solution rather than 5 mL.
The concentration of famotidine in plasma and urine was 
determined by comparing the peak area ratio of famotidine/ 
internal standard (procaine) with a calibration curve. Linear 
calibration curves were always obtained (r2 > 0-99). The inter­
day coefficient of variation (mean of five experiments) varied 
between 2-9 and 5-7% for plasma (concentration range 0-5- 
lO'OjigmL-1 ) and between 2-9 and 7-1% for urine (con­
centration range 5-100 jig mL-1 ). The recovery of famotidine 
from plasma was 89%, that from urine 82%. Accuracy ranged 
from 96*1 to 105-6%.
The limit of quantification and limit of detection were not 
formally assessed because the concentrations used in the 
experiments could easily be detected. The detection limit of 
famotidine was well below 0*05 jig mL_I for plasma and 
0*5|igmL~! for urine.
Binding of famotidine to plasma protein was determined by 
ultrafiltration with Visking dialysis tubing (Russel et al 1987). 
The ultrafiltrates (200 jiL) were treated and analysed in the 
same way as urine samples,
Inulin in urine and plasma samples was assayed according to 
the method of Heyrovski (1956) for calculation of glomerular 
filtration rate.
Pharmacokinetic analysis
Plasma and urine data were analysed separately according to a 
two-compartment model with the non-linear regression pro­
gram Nonlin (Metzler et al 1974). Basic pharmacokinetic 
parameters (clearance and distribution volume) were calcu­
lated model-independently by applying statistical moments 
theory, using standard equations (Gibaldi & Perrier 1982). 
Half-lives (ti) of the drug in plasma and urine were determined 
from the terminal phase. The area under the plasma con­
centrati on~time curve (AUC) and the area under the renal 
excretion rate-time curve (AUR) were determined by inte­
gration after extrapolation of the terminal phase of the curve to 
infinity. The overall renal clearance (CLR) was estimated by 
the total excretion method, by dividing the total amount 
excreted into the urine in infinite time, which equals the AUR, 
by the AUC.
Because passive re-absorption was considered to be negli­
gible, the part of renal famotidine clearance attributable to 
active tubular secretion (Rts) can be calculated by subtracting 
the filtration rate (Rgf) from the total excretion rate (Rr ) for 
each experiment: R ts  =  R r  — R gf-
RGf =  GFR x fu x  Cp, where GFR is the glomerular filtra­
tion rate determined from the inulin clearance, fu is the fraction 
unbound in plasma and Cp is the total plasma concentration. A 
linear plot of Rts against Cp, the so-called tubular titration 
curve, was analysed with Nonlin according to the Michaelis- 
Menten equation:
R ts  =  (Tm x Cp)/(KT +  Cp) (1)
where TM is the maximum transport capacity (|ig m in '1) and 
Kt the Michaelis-Menten constant of the tubular secretion 
mechanism (jigmL-1 ).
Average values are expressed as means =fc s.d. Statistical 
significance was determined by analysis of variance then post 
tests (two-samples i-test with Bonferoni correction). A value of 
P < 0-05 was considered significant.
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Table 1. Pharmacokinetic and experimental parameters characterizing the renal handling of famotidine after intravenous infusion in the dog.
Short-term infusion Continuous infusion
D ogi Dog 2 Dog 3 Dog 1 Dog 2
Weight of dog (kg) 15-1 14*3 15-6 14-8 14-0Dose (mg) 46 67 80 1270 254
Infusion rate (mg min *) 6 6 8 _ * - tGlomerular filtration ratei (mL min-  ) 66 ± 8 26 ± 4 43 ± 7 74 ±13 41 ± 3
Urine flow§ (mL min”  ’) 0-68 ±0-13 0-68 ±0-06 0-65 ±0-12 0-76 ±0-25 0-88 ±0-40Urine pH§
Fraction of dose excreted into
7-57 ±0-20 7-80 ±0-09 7-76 ±0-26 7-51 ±0-12
è
7'67 ±0-12
urine in infinite time (% dose) 
Half-life of terminal phase of
63 47 74 69 52
drug in plasma (min)Total plasma clearance (mL m in "1) 
Renal clearance (mL min” 1)
126 73 93 62 53120 120 148 127 14274 56 101 76 65Distribution volume at steady-state (L) 14*5 8-6 12-7 7*7 8-6
Data are expressed as means ±  s.d. ^Subsequent 85-min infusions of 2-25, 4-50 and 6-75 mg min” 1 famotidine, each preceded by 5 min of 8 mg min-1 famotidine. ‘(•Subsequent 115-min infusions of 0-02 and 2 mg min” 1 famotidine, preceded by 5min of 0*5 and 4 mg m in"1, 
respectively. JAverage of steady-state inulin clearance (n =  7). §Average of all urine samples (n —25).
Results
Increasing doses of famotidine were administered with the 
objective of achieving saturation of tubular secretion. A sum­
mary of the results from all the experiments is given in Table 
1. No clear indications of saturation of the renal clearance were 
observed. The doses of famotidine administered were not 
identical for all dogs. For saturation of active tubular secretion 
we intended to administer very high famotidine doses but the 
size of the dose was limited by cardiovascular side-effects 
caused by the peak famotidine plasma concentrations after 
short-term infusion. A maximum heart rate of 200 beats min“ 1 
was used as an indication of the highest dose that could be 
administered safely to a dog by short-term infusion.
Renal clearance of famotidine was also studied in experi­
ments with continuous famotidine infusion at increasing dos­
ing rates* The infusion schedule and the derived 
pharmacokinetic parameters are given in Table 1. When the 
infusion rate was increased from 2-25 mg min-1 to 
4*5 mg min-1 (dog 1), the mean plasma concentration 
increased from 10-9 ±  1 -5 to 28-4 ±  4-0 |¿g m L "1 and the renal 
clearance decreased from 97 ± 1 4  to 84 ±  5 mL min “ 1. A 
further increase of the infusion rate to 6-75 mg m in '1 (mean 
plasma concentration 46*2 d= 2*8 jigmL” 1) only resulted in a 
minor decrease in renal clearance to 81±5m L m in“ 1. In 
another experiment (dog 2), the infusion rate was increased 
from 0*02 mg m in "1 to 2-0 mg min“ 1, which resulted in an 
increase of mean plasma concentration from 0-17 ±0-03 to 
8-7 ±  1-7 jigmL-1 and a significant reduction of renal clear­
ance from 117 ±  33 to 87 ±  18 mL min“ l . The plots of plasma 
concentration and renal excretion against time for this 
experiment are shown in Fig. 1. These data suggest saturable 
renal clearance of famotidine in the dog. The unbound famo­
tidine fraction in plasma was determined to be 0-72 d= 0-16 
(n=28) and was concentration-independent over a plasma 
concentration range from 0-5 to 50 |igm L -1 .
No evidence of passive re-absorption of famotidine was 
observed. Non-ionic back diffusion seems unlikely under the 
experimental circumstances, because of the relatively high 
urine flow (mannitol-induced) and high urinary pH (7-30-8-00)
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FlG. 1. Renal excretion rate (—) and plasma concentration (• )  as a function of time during continuous inftision of famotidine in beagle 
dogs. Infusion was started at t =  0 min with 5 min of 0-5 mg min 1 then 115 min of 0-02 mg min ” 1 • At t =  120 min, high dose inftision was 
started with 5 min of 4-0 mg min” 1 then 115 min of 2-0 mg min- 1.
as compared with the dissociation constant of famotidine 
(pKa =  6'7; Echizen & Ishizaki 1991). Saturability of renal 
famotidine clearance can be seen clearly from a tubular titra­
tion plot in which the data from all experiments are depicted 
(Fig. 2). In this figure, the active tubular famotidine secretion 
(R ts) is plotted against plasma concentration. Active tubular 
secretion was calculated for each experiment separately by 
subtracting the filtration rate (R gf) fr°m the total excretion rate 
(R r). From this curve it is obvious that the active renal 
excretion of famotidine becomes saturated. A tubular transport 
maximum of 2400 ±  220 jig min ~ 1 and an apparent Michaelis- 
Menten constant of tubular secretion of 26±4[igm L '"1 
(76 ±  12 jiM) were calculated.
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Fig . 2. Tubular titration curve of famotidine in beagle dogs in which the active tubular secretion rate is plotted against the plasma concen­
tration. The line in the figure represents the result of data analysis according to the Michaelis-Menten equation.
Discussion
We demonstrated that the renal clearance of famotidine in the 
dog becomes saturated at high, supratherapeutic, plasma con­
centrations. Saturability was characterized by a maximum 
transport capacity of 2400 ±  220 ng min ” 1 and a Michaelis- 
Menten constant for tubular secretion of 26± 4  jxgmL” 1. To 
the best of our knowledge this is the first study in which 
saturation of famotidine renal clearance has been fully quan­
tified in-vivo.
Famotidine is known as a substrate for the renal organic 
cation transporter. The understanding of the mechanisms 
involved in the renal tubular secretion of organic cations has 
been enlarged by mechanistic studies in cellular and sub- 
cellular experimental models. The first step in proximal tubular 
secretion of organic cations involves entrance into the tubular 
cell across the basolateral membrane by facilitated diffusion or 
by active-carrier-mediated transport (Schäli et al 1983; Tarloff 
& Brand 1986). Transport is assisted by the negative cell 
interior. The organic cation than leaves the cell across the 
brush-border membrane by active carrier-mediated transport 
against the electrochemical gradient (Pritchard & Miller 1993).
In-vitro, famotidine is a potent inhibitor of transport of other 
cationic drugs. The inhibitory constants for transport at the 
brush-border membrane reported in the literature range from 
1-5 to 3*0 fiM for inhibition of tetraethyl ammonium uptake in 
isolated rat proximal tubular cells and membrane vesicles 
(Boom et al 1992; Somogyi et al 1994), inhibition of cimeti­
dine uptake in rat proximal tubular cells (Boom & Russel 
1993) and N 1-methylnicotinamide uptake in canine membrane 
vesicles (Bendayan et al 1990). A much higher value of 
0-20 dc 0-06 mM was observed for inhibition of N-methyl-4- 
phenylpyridinium transport in rat proximal tubules determined 
with the stop-flow microperfusion method (David et al 1995). 
The inhibitory potency of famotidine against basolateral 
organic cation transport is considerably lower and ranges from 
0*1 to 1-OmM for inhibition of N 1 -methylnicotinamide trans­
port in rat proximal tubules determined with stop-flow 
microperfusion (David et al 1995) and inhibition of tetra­
ethyl ammonium and cimetidine uptake in isolated rat proximal 
tubular cells (Boom et al 1992; Boom & Russel 1993). Our 
observed apparent KT value of 76 [iM must be interpreted as an
overall parameter accounting for transport across both the 
basolateral and brush-border membranes.
Although famotidine is a potent cationic drug inhibitor in- 
vitro, renal interactions of famotidine in-vivo have not yet been 
reported, Klotz et al (1985) and Abraham et al (1987) showed 
that famotidine in therapeutic doses did not inhibit the renal 
elimination of procainamide, N-acetylprocainamide and crea­
tinine, probably because of the low famotidine plasma con­
centrations ( < 0-3 pgm L“ 1) used in these studies. In the rat, 
famotidine in a steady-state concentration of 50-94 jjigmL“ 1 
did not reduce the renal clearance of cimetidine (1*2- 
3*8 jig mL“ 1), whereas cimetidine at a steady-state con­
centration of 112-250 jig mL ""1 reduced the renal clearance of 
famotidine (0-11-0*5 |xg mL-1 ) by 70% (Lin et al 1988). These 
apparently contradictory results can be explained by compar­
ing plasma concentrations and affinities for the organic cation 
transport system. In the experiment with cimetidine as inhi­
bitor, the ratio of inhibitor drug to inhibited drug was much 
higher than in the experiment with famotidine as inhibitor. A 
high apparent Michaelis-Menten constant for tubular secretion 
of 0*8 \xu was, moreover, reported for cimetidine in the iso­
lated perfused rat kidney (Boom et al 1994). The tubular 
transport maximum of famotidine in the rat was 180 |xg min “ 1 
kg“ 1 (Lin et al 1987), which is in agreement with our value of 
2400 jig min“ 1, which corresponds to 162 jig min“ 1 kg^1.
In summary, it is clear from the results in this paper that 
therapeutic plasma concentrations of famotidine, which in 
general are below 0*1 jig mL~ \  are not high enough to saturate 
tubular secretion or to compete with the renal transport of other 
cationic drugs whose therapeutic concentrations are usually 
much higher, even though the affinity of famotidine for the 
organic cation transporter is relatively high. Clinically 
important renal interactions with the use of famotidine are 
therefore not to be expected.
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